get a foot in the door 😬
but had to $REGN (+0,98 %) had to make way 😁
Postes
22get a foot in the door 😬
but had to $REGN (+0,98 %) had to make way 😁
Hello to the community ✌️
I would like to reduce the size of my portfolio.
my portfolio currently consists of 1 ETF and 40 individual shares.
my goal is to reduce the number of individual stocks to around 30-32 positions over time 🤔
There are currently 2 positions at the top of the closing list
I would like to add 2,3 more positions, but unfortunately I don't have the imagination to get rid of them 😅
Maybe with the help of the community here, to make the decision a little easier😬
On the other hand, I also want to $COST (+0,37 %) & $WM (-0,35 %) despite the still high valuations, but they are absolute Dauerläufer🤷🏼♂️
What are your opinions?
which positions would you throw out?
and why exactly these?
Thank you !
The semi-annual rebalancing of the SPDR S&P Developed Quality Aristocrats ETF ($QDEV (+0,65 %) ) has just been completed, bringing notable changes to the composition of this quality-focused investment vehicle.
Outgoing Companies:
Incoming Companies:
This rebalancing aligns QDEV with evolving market conditions while maintaining its focus on quality companies with strong financial foundations. For investors seeking exposure to financially robust global corporations, these changes appear strategically sound, particularly with the inclusion of resilient tech giants and hospitality leaders positioned for growth.
Will this prove to be a winning choice? The fundamentals certainly suggest so.
- Revenue: $3.79B, +10% YoY
- Net income: $918M, -21% YoY
- GAAP EPS: $8.06 vs $10.19 in Q4 2023
- Non-GAAP EPS: $12.07, +2% YoY
CEO Leonard S. Schleifer: "Regeneron's financial and commercial strength allows for continued investment in our industry-leading R&D pipeline, while simultaneously returning capital to our shareholders through our newly initiated dividend program and increased share repurchase capacity."
🌱Revenue & Growth
- EYLEA HD & EYLEA U.S. sales: $1.50B, +2% YoY
- Dupixent global sales: $3.70B, +15% YoY
- Libtayo global sales: $367M, +50% YoY
- Sanofi collaboration revenue: $1.21B, +22% YoY
💰Profits & Financials
- GAAP R&D expenses: $1.41B, +20% YoY
- GAAP gross margin: 84-85%
- Cash and marketable securities: $17.91B
- Share repurchase: $976M in Q4, $2.6B in FY2024
📌Business Highlights
- Initiated quarterly dividend program ($0.88 per share)
- Increased share repurchase capacity to ~$4.5B
- Submitted regulatory applications for EYLEA HD pre-filled syringe, Dupixent in bullous pemphigoid
my friends, we have a lot to look forward to next week for the start of February 2025 🤯
what did you think of the earnings this week?
what are you expecting next week?
What company figures are you looking forward to? 🧐
for me
Tuesday : $AMD (+0,11 %)
$GOOGL (+0 %)
$REGN (+0,98 %)
$MRK (+0,42 %)
Wednesday: $QCOM (-0,06 %)
$NOVO B (-1,67 %)
Thursday: $AMZN (+0,47 %)
$ELF (+2,2 %)
UP📈 or DOWN 📉 ?
have a nice weekend ! ✌️
Unfortunately, the money was only enough for 1 share $REGN (+0,98 %) was enough 🥲
let's see where the journey goes 🛫
$NBIX (+1,94 %)
$REGN (+0,98 %) Is there anyone here who is invested in Neurocrine or Regeneron?
The shares seem to be attractively priced at the moment and the companies appear to be financially sound. However, I'm not that familiar with the sector yet.
I would therefore be grateful for any opinions.
I came up with a crazy idea and I wanted to share my work with you. I decided to organize my watchlist according to different criteria. The best stock gets 10 points and the worst gets 1 point. It is important to mention that this is a snapshot and can change at any time.
The criteria were:
- Market value (the higher the better as with the s&p)
- 52W low difference
- 52W high difference (at least 15 percent 52 w of high)
- Wallstreet rating ( strong buy )
- Price Target Difference
- Z score
- Sales forecast for the next 5 years
- EPS forecast for the next 5 years
- Forward PE ( the lower the better )
- ROIC ( the higher the better)
- Gross profit margin ( the higher the better)
- Net margin ( the higher the better)
-FCF margin ( the higher the better)
- Profit per employee ( the higher the better)
- PEG Ratio ( the lower the better)
- Beta (the lower the better)
- FCF Yield (the higher the better)
- Earning Yield ( the higher the better)
- Current ratio ( the higher the better)
-Short ratio ( the lower the better)
- Quick ratio ( the higher the better)
- Debit / EBITDA (the lower the better)
Place 1- $LRCX
2nd place $SNPS (+3,28 %)
3rd place 3- $NOVO B (-1,67 %)
Place 4- $MCHP (+0,08 %)
5th place $REGN (+0,98 %)
Place 6- $MCK (+0,1 %)
ATTENTION: many industries cannot be compared directly, which is why, for example, gastronomy providers perform relatively poorly in such a test or the transportation sector such as ODFL. Here you can only compare shares from the same sector.
I would be very interested to know what you think of my approach? What can be done better here to achieve even more accurate results? Which criteria would you use and which not?
I am very curious about your feedback.
Thank you very much in advance 😘
$REGN (+0,98 %) Hello community. What do you think of this company? Somehow it's quiet in chats about the company.
Meilleurs créateurs cette semaine